Shape-Shifting Drug Supercharges Cancer Treatment in Mice

Researchers at Washington University School of Medicine used click chemistry to assemble existing antibody-drug conjugates inside the body after injection.

The modular system can bind multiple cancer targets, including EGFR and HER2, instead of relying on a single target.

In mouse models of pancreatic, gastric, and breast cancer, it delivered more drug to tumors and outperformed standard treatments.

The approach could offer a more adaptable way to treat mixed, treatment-resistant tumors by reusing approved antibody components.